<DOC>
	<DOCNO>NCT01755572</DOCNO>
	<brief_summary>Purpose : The purpose study study mechanism liraglutide , relatively new anti-hyperglycemic medication , might lower blood pressure patient Type 2 diabetes high blood pressure .</brief_summary>
	<brief_title>Blood Pressure Outcomes With Liraglutide Therapy</brief_title>
	<detailed_description>Background : Type 2 diabetes worldwide health problem . As reduction blood pressure couple improvement overall cardiovascular outcome , control hypertension become important modifiable risk factor overall care patient Type 2 Diabetes , addition glycemic control . Recently , several large-scale clinical trial evaluate glucose-lowering effect anti-hyperglycemic agent , liraglutide ( glucagon-like peptide-1 receptor agonist ) , demonstrate modest yet persistent anti-hypertensive effect patient Type 2 diabetes . Study Objectives : Accordingly , goal small study understand whether blood pressure lower effect liraglutide couple release vasoactive mediator may stimulate natriuresis and/or diuresis lower systolic blood pressure . Study Design : Randomized , double-masked , cross-over study treatment liraglutide placebo 3 week , intervene washout period 3 week , cross-over identical treatment placebo liraglutide 3 week . Study Patients : 20 patient Type 2 Diabetes Systolic Hypertension Endpoints : Change vasoactive hormone , 24-hour ambulatory blood pressure , urinary sodium excretion pattern .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>1 . Men woman age 3070 . 2 . Patients Type 2 Diabetes [ diagnose physician ] serum HbA1c ≥ 6.5 % ≤ 10 % . 3 . Patients currently prescribe 02 oral hypoglycemic agent physician . 4 . Patients systolic blood pressure ≥ 130 mmHg ≤ 180 mmHg measure automate oscillometric blood pressure device [ BPTru® DinaMAP® ] . 1 . Individuals Type 1 Diabetes , [ secondary form diabetes include gestational diabetes , transplantassociated , glucocorticoidassociated , latentonset diabetes adult , know monogenic form diabetes ] . 2 . Elevated LVEDP ( leave ventricular enddiastolic pressure ) include congestive heart failure , cardiomyopathy , atrial fibrillation , valvular heart disease ( rat echocardiography and/or clinically cardiologist moderate severe nature ) , elevate RVEDP ( right ventricular enddiastolic pressure ) include pulmonary hypertension . 3 . Moderate renal failure dysfunction indicate serum creatinine &gt; 150 μmol/l , and/or estimate GFR ( Glomerular Filtration Rate ) less 59 ml/min per 1.73m2 . 4 . Individuals secondary form hypertension include primary hyperaldosteronism , renal artery stenosis , obstructive sleep apnea , pheochromocytoma , hyperthyroidism , acromegaly , exogenous systemic glucocorticoid use , hypercortisolism . 5 . Current pregnancy , recent pregnancy within last 3 month , current breastfeeding . Female patient child bear potential [ premenopausal , surgically sterile ] unwillingly baseline serum pregnancy test , and/or unwillingly use active contraception throughout duration study . 6 . Use within last 3 month DPPIV ( Dipeptidyl Peptidase ) inhibitor , GLP1 receptor agonist [ liraglutide , exenatide ( ExBID , Ex QW ) ] , insulin [ bolus , premixed , prandial ] . 7 . Liver failure , include liver cirrhosis nonalcoholic fatty liver disease . 8 . Dependence upon alcohol , &gt; 14 serving per week male , &gt; 9 serving per week female . 9 . Prior history clinical presentation consistent pancreatitis [ acute chronic ] , history medullary thyroid cancer , ccell hyperplasia history multiple endocrine neoplasia syndromes predisposes medullary thyroid cancer [ Multiple Endocrine Neoplasia Type 2 ] . 10 . Individuals severe systolic hypertension , SBP ( systolic blood pressure ) ≥ 181 mmHg measure automate oscillometric blood pressure device [ BPTru® DinaMAP® ] . 11 . Individuals severe diastolic hypertension , DBP ( diastolic blood pressure ) ≥ 100 mmHg measure automate oscillometric blood pressure device [ BPTru® DinaMAP® ] . 12 . Individuals currently prescribe insulin secretagogue [ sulphonylurea ] unwillingly decrease dose 50 % prior start , duration study . 13 . Individuals rest tachycardia &gt; 100 bpm individual prior history know conduction abnormality associate tachycardia include atrial fibrillation , atrial flutter , prolongation PR interval , ventricular tachycardia . 14 . Current involvement , recent involvement [ within 3 month ] clinical trial involve investigational product . 15 . Unwillingness perform daily sc injection study drug therapy duration 21 day throughout 2 treatment phase . 16 . Individuals currently take take diuretic therapy past 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Liraglutide</keyword>
	<keyword>GLP-1</keyword>
</DOC>